DRAFT

Behavioral Social Neuroscience Seminar

Thursday, March 13, 2014
4:00pm to 5:00pm
Add to Cal
Beckman Behavioral Biology B180
Neuroimaging Genetic Biomarkers of Addiction
Elliot A. Stein, National Institute of Drug Abuse,
As for other neuropsychiatric disorders, there are no biomarkers that can quantitatively measure nicotine addiction severity or can track the development of addiction from 'casual' initial use to dependence. As such, no quantitative means to predict treatment outcome success exists, which may at least partially accounts for the enormous recidivism in addiction treatment (>80% in one month and 95% after 6 months). Dr. Stein will present recent data from his lab using both task-based and resting state fMRI, together with behavioral, personality measures and genetic polymorphisms with the long-term goal of developing a brain-based biomarker of addiction. The overarching hypothesis is that as addiction is thought to be a disease of maladaptive neuroplasticity, resultant brain structural and functional changes will not only be detectable using MRI based measures, alterations in these markers will reflect the 'reversibility' or compensatory changes that occur along the abstinence trajectory.
For more information, please contact Barbara Estrada by phone at Ext. 4083 or by email at bestrada@hss.caltech.edu.